Consequently, when designing therapeutic strategies targeting SIRPα-overexpressing cancers, it is critical to consider not only the immunostimulatory effects of SIRPα inhibition on myeloid cell-mediated immunity within the tumor microenvironment but also its direct impact on tumor cells and whether such effects may counteract potential immunotherapeutic benefits. The gene discussed is SIRPA; the disease is cancer.